坦索罗辛单药治疗后加用索利那新对良性前列腺增生伴膀胱过度活动症的应用价值分析

Analysis of the application value of tamsulosin and solifenacin for benign prostatic hyperplasia complicated with overactive bladder

目的探讨坦索罗辛单药治疗后加用索利那新对良性前列腺增生(BPH)伴膀胱过度活动症(OAB)的应用价值。方法 120例良性前列腺增生伴膀胱过度活动症患者,随机分为对照组与观察组,每组60例。对照组单用坦索罗辛治疗,观察组采用坦索罗辛联合索利那新治疗。比较两组患者的症状改善情况、尿流动力学参数改变情况、不良反应发生情况。结果观察组治疗后国际前列腺症状评分(IPSS)、储尿期症状评分(USPSS)、排尿期症状评分(VSS)、膀胱过度活动症评分(OABSS)(9.6±1.4)、(8.5±1.3)、(8.3±1.7)、(5.9±1.2)分均优于对照组的(15.5±2.1)、(12.4±1.9)、(14.1±2.5)、(7.2±1.4)分,差异均具有统计学意义(P<0.05)。观察组治疗后最大尿流率(Qmax)、平均尿流率(Qave)、尿量(UV)、残余尿量(13.98±2.32)ml/s、(7.28±1.76)ml/s、(265.7±12.2)ml、(26.4±7.5)ml均优于对照组的(11.69±1.47)ml/s、(5.87±2.01)ml/s、(223.5±13.4)ml、(38.2±8.1)ml,差异均具有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论坦索罗新单药治疗后加用索利那新对良性前列腺增生伴膀胱过度活动症效果显著,利于排尿功能的改善,症状缓解效果确切,不良反应可控,具有积极的临床意义。

Objective To investigate the application value of tamsulosin and solifenacin for benign prostatic hyperplasia（BPH） complicated with overactive bladder（OAB）. Methods A total of 120 patients with benign prostatic hyperplasia complicated with overactive bladder were randomly divided into control group and observation group, with 60 cases in each group. The control group was treated with tamsulosin, and the observation group was treated with tamsulosin and solifenacin. Comparison were made on symptoms improvement, changes in urodynamic parameters, and occurrence of adverse events between the two groups. Results After treatment, the observation group had better International Prostatic Symptom Score（IPSS）, storage symptom score（USPSS）, voiding symptoms score（VSS） and overactive bladder score（OABSS） as（9.6±1.4）,（8.5±1.3）,（8.3±1.7） and（5.9±1.2） points than（15.5±2.1）,（12.4±1.9）,（14.1±2.5） and（7.2±1.4） points, and the difference was statistically significant（P〈0.05）. After treatment, the observation group had maximum urine flow rate（Qmax）, mean urine flow rate（Qave）, urine volume（UV）, residual urine volume as（13.98±2.32） ml/s,（7.28±1.76） ml/s,（265.7±12.2） ml and（26.4±7.5） ml than（11.69±1.47） ml/s,（5.87±2.01） ml/s,（223.5±13.4） ml and（38.2± 8.1） ml in the control group, and their difference was statistically significant（P〈0.05）. Both groups had no statistically significant difference in incidence of adverse reactions（P〈0.05）. Conclusion Application of tamsulosin and solifenacin shows remarkable effect for benign prostatic hyperplasia complicated with overactive bladder. It is beneficial to improve voiding function with accurate symptomatic relief effect and controllable adverse reaction. It contains positive clinical significance.